References
1. World Health Organization (WHO). WHO coronavirus disease (COVID-19) dashboard [Internet]. Geneva: WHO; 2020 [accessed 30 Dec 2020]. Available from: https://covid19.who.int.2. Langford B, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622-9.3. van Staa TP, Palin V, Li Y, Welfare W, Felton TW, Dark P, et al. The effectiveness of frequent antibiotic use in reducing the risk of infection-related hospital admissions: results from two large population-based cohorts. BMC Med. 2020;18:40.4. Oldenburg CE, Doan T. Azithromycin for severe COVID-19. Lancet. 2020;396:936-7.5. Furtado RHM, Berwanger O, Fonseca HA, Correa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396:959-67.6. World Health Organization (WHO). Global Action Plan on Antimicrobial Resistance. Geneva: WHO; 2015. 7. Peraturan Menteri Kesehatan Republik Indonesia Nomor 8 tahun 2015. Program Pengendalian Resistensi Antimikroba di Rumah Sakit. Jakarta: Kemenkes RI; 2015.8. Lardo S, Chen LK, Santoso WD, Rumende CM. Hubungan kualitas penggunaan antibiotik menggunakan alur Gyssens dengan keberhasilan pengobatan pada sepsis MDR gram negatif di rumah sakit tersier. JPDI. 2020;7(4):221-7.9. Holmes AH, Moore LSP, ord AnS, Steinbakk M, Regmi S, Karkey A. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387:176–87.
Recommended Citation
Sinto, Robert
(2020)
"Peran Penting Pengendalian Resistensi Antibiotik pada Pandemi COVID-19,"
Jurnal Penyakit Dalam Indonesia: Vol. 7:
Iss.
4, Article 1.
DOI: 10.7454/jpdi.v7i4.533
Available at:
https://scholarhub.ui.ac.id/jpdi/vol7/iss4/1
